Roberta Melander

Dr. Roberta Melander

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2017 in MedChemComm
Verified
Journal Article
Open access
PDF file
RMRoberta Melander
Roberta Melander
DZDaniel V. Zurawski
Daniel V. Zurawski
CMChristian Corey Melander
Christian Corey Melander
While broad spectrum antibiotics play an invaluable role in the treatment of bacterial infections, there are some drawbacks to their use, namely selection for and spread of resistance across multiple bacterial species, and the detrimental effect they can have upon the host microbiome. If the causative agent of the infection is known, the use of narrow-spectrum antibacterial agents has the potential to mitigate some of these issues. This review outlines the advantages and challenges of narrow-spectrum antibacterial agents, discusses the progress that has been made toward developing diagnostics to enable their use, and describes some of the narrow-spectrum antibacterial agents currently being investigated against some of the most clinically important bacteria including Clostridium difficile, Mycobacterium tuberculosis and several ESKAPE pathogens.

19 April 2019 in ACS Infectious Diseases
Verified
Journal Article
Open access
SMSara E. Martin
Sara E. Martin
RMRoberta Melander
Roberta Melander
CBChristopher M. Brackett
Christopher M. Brackett
ASAlison J. Scott
Alison J. Scott
CCCourtney E. Chandler
Courtney E. Chandler
CMChristian Corey Melander
Christian Corey Melander
In 2016, the World Health Organization deemed antibiotic resistance one of the biggest threats to global health, food security, and development. The need for new methods to combat infections caused by antibiotic resistant pathogens will require a variety of approaches to identifying effective new therapeutic strategies. One approach is the identification of small molecule adjuvants that potentiate the activity of antibiotics of demonstrated utility, whose efficacy is abated by resistance, both acquired and intrinsic. To this end, we have identified compounds that enhance the efficacy of antibiotics normally ineffective against Gram-negative pathogens because of the outer membrane permeability barrier. We identified two adjuvant compounds that dramatically enhance sensitivity of Acinetobacter baumannii to macrolide and glycopeptide antibiotics, with reductions in minimum inhibitory concentrations as high as 256-fold, and we observed activity across a variety of clinical isolates. Mode of action studies indicate that these adjuvants likely work by modulating lipopolysaccharide synthesis or assembly. The adjuvants were active in vivo in a Galleria mellonella infection model, indicating potential for use in mammalian infections.

1 March 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
TNTri-Dung Nguyen
Tri-Dung Nguyen
MBMeghan Blackledge
Meghan Blackledge
ELErick A. Lindsey
Erick A. Lindsey
BMBradley M. Minrovic
Bradley M. Minrovic
DADavid F. Ackart
David F. Ackart
CMChristian Corey Melander
Christian Corey Melander
A library of 2‐aminobenzimidazole derivatives was screened for the ability to suppress β‐lactam resistance in Mycobacterium smegmatis. Several non‐bactericidal compounds were identified that reversed intrinsic resistance to β‐lactam antibiotics in a manner distinct from β‐lactamase inhibitors. Activity also translates to M. tuberculosis, with a lead compound from this study potently suppressing carbenicillin resistance in multiple M. tuberculosis strains (including multidrug‐resistant strains). Preliminary mechanistic studies revealed that the lead compounds act through a mechanism distinct from that of traditional β‐lactamase inhibitors.

12 February 2019 in MedChemComm
Verified
Journal Article
Closed access
PDF file
TNT. Vu Nguyen
T. Vu Nguyen
MPMatthew T. Peszko
Matthew T. Peszko
RMRoberta Melander
Roberta Melander
CMChristian Corey Melander
Christian Corey Melander
Biofilm formation by mycobacteria can lead to enhanced antibiotic tolerance. Herein, we report on the identification of a series of 2-aminobenzimidazole (2-ABI) derivatives that potently inhibit biofilm formation by Mycobacterium smegmatis.

8 October 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
BKBeverly H. Koller
Beverly H. Koller
LJLeigh A. Jania
Leigh A. Jania
HLHaoting Li
Haoting Li
WBWilliam T. Barker
William T. Barker
RMRoberta Melander
Roberta Melander
CMChristian Corey Melander
Christian Corey Melander
Antimicrobial resistance (AMR) has led to a marked reduction in the effectiveness of many antibiotics, representing a substantial and escalating concern for global health. Particularly alarming is resistance in Gram-negative bacteria due to the scarcity of therapeutic options for treating infections caused by these pathogens. This challenge is further compounded by the rising incidence of resistance to colistin, an antibiotic traditionally considered a last resort for the treatment of multi-drug resistant (MDR) Gram-negative bacterial infections. In this study, we demonstrate that adjuvants restore colistin sensitivity in vivo . We previously reported that the salicylanilide kinase inhibitor IMD-0354, which was originally developed to inhibit the human kinase IKKβ in the NFκB pathway, is a potent colistin adjuvant. Subsequent analog synthesis using an amide isostere approach led to the creation of a series of novel benzimidazole compounds with enhanced colistin adjuvant activity. Herein, we demonstrate that both IMD-0354 and a lead benzimidazole effectively restore colistin susceptibility in mouse models of highly colistin-resistant Klebsiella pneumoniae and Acinetobacter baumannii -induced peritonitis. These novel adjuvants show low toxicity in vivo , significantly reduce bacterial load, and prevent dissemination that could otherwise result in systemic infection.

Verified
Journal Article
Open access
PDF file
EHElizabeth I. Harper
Elizabeth I. Harper
MSMichael D. Siroky
Michael D. Siroky
THTyvette Hilliard
Tyvette Hilliard
GDGena M. Dominique
Gena M. Dominique
CHCatherine Hammond
Catherine Hammond
MSM. Sharon Stack
M. Sharon Stack
Ovarian cancer is the sixth leading cause of cancer-related death in women, and both occurrence and mortality are increased in women over the age of 60. There are documented age-related changes in the ovarian cancer microenvironment that have been shown to create a permissive metastatic niche, including the formation of advanced glycation end products, or AGEs, that form crosslinks between collagen molecules. Small molecules that disrupt AGEs, known as AGE breakers, have been examined in other diseases, but their efficacy in ovarian cancer has not been evaluated. The goal of this pilot study is to target age-related changes in the tumor microenvironment with the long-term aim of improving response to therapy in older patients. Here, we show that AGE breakers have the potential to change the omental collagen structure and modulate the peritoneal immune landscape, suggesting a potential use for AGE breakers in the treatment of ovarian cancer.